California Public Employees Retirement System Sells 4,440 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

California Public Employees Retirement System cut its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.0% during the 4th quarter, Holdings Channel reports. The firm owned 107,729 shares of the company’s stock after selling 4,440 shares during the period. California Public Employees Retirement System’s holdings in CRISPR Therapeutics were worth $6,744,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of CRSP. CWM LLC grew its position in shares of CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after buying an additional 260 shares during the last quarter. Tradewinds Capital Management LLC increased its position in CRISPR Therapeutics by 545.5% during the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after purchasing an additional 600 shares during the period. Blue Trust Inc. bought a new position in CRISPR Therapeutics in the 4th quarter worth $32,000. Headlands Technologies LLC purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth about $34,000. Finally, Bourgeon Capital Management LLC boosted its stake in shares of CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $55.89 on Friday. The firm has a 50-day simple moving average of $67.75 and a two-hundred day simple moving average of $64.17. The firm has a market cap of $4.74 billion, a P/E ratio of -28.52 and a beta of 1.80. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. CRISPR Therapeutics’s revenue was up 3253.3% on a year-over-year basis. During the same period last year, the business earned ($1.41) EPS. On average, equities research analysts predict that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Samarth Kulkarni sold 19,582 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Raju Prasad sold 3,524 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the transaction, the chief financial officer now owns 6,476 shares in the company, valued at approximately $470,740.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 83,992 shares of company stock valued at $6,132,335. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the subject of several research analyst reports. Royal Bank of Canada raised their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Mizuho raised their target price on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Morgan Stanley upped their price target on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research note on Monday, February 26th. Wells Fargo & Company raised their price objective on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Finally, Wolfe Research began coverage on shares of CRISPR Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $76.29.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.